Sunesis Pharmaceuticals Культура компании

Mr. Daniel N. Swisher Jr., also known as Dan, has been President and chief operating officer of Jazz Pharmaceuticals plc since January 03, 2018. Mr. Swisher has been Strategic Advisor of Sunesis Pharmaceuticals, Inc. since January 1, 2018. Previously, Mr. Swisher served as Chief Executive Officer at Sunesis Pharmaceuticals, Inc. from January 2004 to December 31, 2017 and its President from August 2005 to December 31, 2017. Mr. Swisher has more than 25 years of experience in pharmaceutical product development, commercialization and finance. He served as a Corporate Secretary of Sunesis Pharmaceuticals, Inc. until December 31, 2017. He joined Sunesis Pharmaceuticals in 2001 and served as its Chief Business Officer & Chief Financial Officer from December 2001 to December 2003. He served as the Chief Operating Officer of Sunesis. He joined Sunesis in 2001. From June 1992 to September 2001, he served in various management roles at ALZA Corporation. Mr. Swisher served as Senior Vice President of Sales & Marketing of ALZA Corporation from 2000 to September 2001 and previously served as Vice President of its Marketing from 1997 to 1999 and Executive Director of its New Product Planning from 1995 to 1997. He has been Chairman of Cerus Corporation since October 21, 2013. He has been an Independent Director of Corcept Therapeutics Incorporated since June 22, 2015 and Cerus Corporation since June 2011. He has been a Director of Sunesis Pharmaceuticals, Inc. since 2003. He worked in Marketing at Baxter International. He began his career in various investment positions with Prudential Investment Corporation. Mr. Swisher holds a B.A. degree in History from Yale University and an MBA from the Stanford Graduate School of Business.

Mr. William P. Quinn, also known as Willie, has been the Chief Financial Officer and Senior Vice President of Finance & Corporate Development at Sunesis Pharmaceuticals, Inc. since November 30, 2017. Mr. Quinn began his career in the life science industry at Novation Biosciences. From 2003 to 2011, he held various management positions at Jazz Pharmaceuticals. His role included strategy development and execution as Jazz transformed from a raw startup to a public, profitable specialty pharma company. He served as the Chief Executive Officer and President of Bullet Biotechnology Inc. Before Jazz, he served as the Chief Operating Officer and Chief Financial Officer of Novation Biosciences, a biotech software company that was acquired by Agilent Technologies. He serves as a Director of Bullet Biotechnology Inc. He first developed his interest in Life Sciences while he was an Associate Partner at Mobius Venture Capital. He serves as a Director and Treasurer of A Foundation Building Strength, a nonprofit organization dedicated to finding treatments for Nemaline Myopathy, a congenital neuromuscular disorder that causes severe muscle weakness. He also serves as a Director for Midnight Pharma and Neurogastrx and has served as an Advisor to UCSF's T1 Catalyst Program and Stanford's SPARK program. Mr. Quinn holds an MBA from Stanford Graduate School of Business and an MA and BA from Stanford University.

Dr. Deborah A. Thomas, also known as Debbie, Ph.D., has been Senior Vice President of Regulatory Affairs, Quality Assurance and Non-Clinical Development at Sunesis Pharmaceuticals, Inc. since February 19, 2016. Dr. Thomas served as Vice President of Regulatory Affairs & Medical Writing at Sunesis Pharmaceuticals, Inc. until February 19th 2016. Dr. Thomas served as Vice President of Regulatory Affairs of Sunesis Pharmaceuticals, Inc since October 02, 2012. Dr. Thomas was the Vice President of Regulatory Affairs at BiPar Sciences, Inc. since October 2007. Dr. Thomas joined Sunesis in November 2011 as Executive Director, Regulatory Affairs. Dr. Thomas spent the previous 17 years at Genentech, where she held senior positions in Toxicology, Product Portfolio Management, and Regulatory Affairs. Dr. Thomas served in various management positions at Genentech, Inc. from 1990 to 2007. As a Senior Director in clinical Regulatory Affairs of Genentech, Dr. Thomas oversaw products moving from late-stage research and development into Phase I clinical testing. She served as Project Team Leader for Avastin, Omnitarg, pertuzumab and Raptiva in the Product Portfolio Management Department. She began her career in the pharmaceutical industry as a Toxicologist at Syntex Research. She is a board-certified Diplomate of the American Board of Toxicology. Dr. Thomas received her PhD in Toxicology and her B.S. in Microbiology from the University of Kentucky. Dr. Thomas completed her Postdoctoral training at the Chemical Industry Institute of Toxicology (CIIT) in Research Triangle Park, North Carolina.

Dr. Judith A. Fox, also known as Judy, Ph.D., serves as Senior Vice President of Research & Development at Amphivena Therapeutics, Inc. Dr. Fox has been Chief Scientific Officer at Sunesis Pharmaceuticals, Inc. since 2017. Dr. Fox served as Vice President of Development at Sunesis Pharmaceuticals, Inc. Dr. Fox served as Vice President of Product & Preclinical Development of Sunesis Pharmaceuticals Inc., since June 2008. Dr. Fox joined Sunesis in 2006 as Senior Director and Program Leader. Previously, she served as Senior Director in the Translational Sciences Department for Chiron Corporation (now Novartis AG) from 2005 to 2006, where she led the clinical pharmacology and preclinical pharmokinetics (PK)/drug metabolism group, supporting the development of Chiron Corporation's novel oncology compounds. From 2002 to 2005, Dr. Fox served as Senior Director/Senior Staff Scientist for Genencor International, where she started the Pharmacological Sciences Department. Dr. Fox's industry career began in the PK/Metabolism Department for Genentech, where she ultimately led the group responsible for all oncology projects from late-stage research through clinical development. During her ten years at Genentech, she contributed to the development of products such as Herceptin(R), Xolair(R), Raptiva(R) and Avastin(R). Dr. Fox received her PhD in Biological Chemistry from the Massachusetts Institute of Technology and an A.B. in Chemistry from Bryn Mawr College. She conducted postdoctoral research at The Rockefeller University.

Willie Quinn serves as the CFO & SVP Corporate Development for Sunesis Pharmaceuticals, Inc.. Willie started at Sunesis Pharmaceuticals, Inc. in November of 2017. Willie is based in the San Francisco Bay Area.

Judy Fox serves as the Chief Scientific Officer for Sunesis Pharmaceuticals, Inc.. Judy started at Sunesis Pharmaceuticals, Inc. in March of 2017. Judy is based in the San Francisco Bay Area.

Steve Carchedi serves as the Director- Board of Directors of Sunesis Pharmaceuticals, Inc.. Steve started at Sunesis Pharmaceuticals, Inc. in June of 2013. Steve currently resides in the Greater Philadelphia Area.